Literature DB >> 32462546

Protective Effect of a Novel (2S, 3R, 4S)-Chromene-3-Carboxamide Derivative, Z20 Against Sepsis-Induced Organ Injury.

Liyan Zeng1,2, Yuhang Wang1, Na Li3, Mengwei Niu3, Yong Wang4, Peng Chen5.   

Abstract

Sepsis, a systemic inflammatory response mediated by excessive production of diverse inflammatory cytokines, remains the vital cause of morality in the intensive care unit (ICU). TLR4-MD2 (toll-like receptor 4-myeloid differentiation factor 2) complex activated by LPS serves as an effective target to decrease the inflammation during sepsis. In this study, we evaluated the effects of a new small molecule Z20 structural based on (2S, 3R, 4S)-chromene-3-carboxamide on LPS-induced sepsis in mice. We found Z20 markedly improved the survival rate and attenuated the multiply organs injury after LPS administration in mice. In addition, Z20 significantly alleviated organ inflammation as characterized by diminished inflammatory factors expression in vivo. Furthermore, by employing surface plasmon resonance (SPR) experiment, we identified that TLR4-MD2 complex was the potential target for Z20. Finally, we performed the safety assessment experiment to confirm the safety of Z20 in vivo. In conclusion, Z20, as a potential TLR4-MD2 inhibitor, effectively attenuated LPS-induced organ injury and inflammation.

Entities:  

Keywords:  TLR4-MD2; anti-inflammation; inflammatory cytokine; organ injury; sepsis

Mesh:

Substances:

Year:  2020        PMID: 32462546     DOI: 10.1007/s10753-019-01174-z

Source DB:  PubMed          Journal:  Inflammation        ISSN: 0360-3997            Impact factor:   4.657


  21 in total

Review 1.  Sepsis: definition, epidemiology, and diagnosis.

Authors:  Andrew Lever; Iain Mackenzie
Journal:  BMJ       Date:  2007-10-27

2.  Leptin and interleukin-6 in sepsis.

Authors:  D J Torpy; S R Bornstein; G P Chrousos
Journal:  Horm Metab Res       Date:  1998-12       Impact factor: 2.936

3.  Epidemiology of sepsis and infection in ICU patients from an international multicentre cohort study.

Authors:  Corinne Alberti; Christian Brun-Buisson; Hilmar Burchardi; Claudio Martin; Sergey Goodman; Antonio Artigas; Alberto Sicignano; Mark Palazzo; Rui Moreno; Ronan Boulmé; Eric Lepage; Roger Le Gall
Journal:  Intensive Care Med       Date:  2001-12-04       Impact factor: 17.440

Review 4.  Toll-like receptors: promising therapeutic targets for inflammatory diseases.

Authors:  Asma Achek; Dhanusha Yesudhas; Sangdun Choi
Journal:  Arch Pharm Res       Date:  2016-08-11       Impact factor: 4.946

5.  Diastereoselective Synthesis of 3,4-Dihydropyran-3-carboxamides with in Vitro Anti-inflammatory Activity.

Authors:  Li-Yan Zeng; Baomin Xi; Kaiqi Huang; Jingjie Bi; Lan Wei; Chun Cai; Shuwen Liu
Journal:  ACS Comb Sci       Date:  2019-09-11       Impact factor: 3.784

Review 6.  The "cytokine profile": a code for sepsis.

Authors:  Luis Ulloa; Kevin J Tracey
Journal:  Trends Mol Med       Date:  2005-02       Impact factor: 11.951

Review 7.  The immunopathogenesis of sepsis.

Authors:  Jonathan Cohen
Journal:  Nature       Date:  2002 Dec 19-26       Impact factor: 49.962

Review 8.  LPS/TLR4 signal transduction pathway.

Authors:  Yong-Chen Lu; Wen-Chen Yeh; Pamela S Ohashi
Journal:  Cytokine       Date:  2008-03-04       Impact factor: 3.861

9.  Statins, inflammation, and sepsis: hypothesis.

Authors:  Yaniv Almog
Journal:  Chest       Date:  2003-08       Impact factor: 9.410

10.  Assessing available information on the burden of sepsis: global estimates of incidence, prevalence and mortality.

Authors:  Issrah Jawad; Ivana Lukšić; Snorri Bjorn Rafnsson
Journal:  J Glob Health       Date:  2012-06       Impact factor: 4.413

View more
  1 in total

1.  Antifungal Treatment Aggravates Sepsis through the Elimination of Intestinal Fungi.

Authors:  Baifa Sheng; Yihui Chen; Lihua Sun; Peng Xu; Ben Han; Xiaolong Li; Jiuheng Yin; Teming Li; Haidi Guan; Shuaishuai Chen; Qi Wang; Chuangen Li; Shiqiang Li; Xianhong Jiang; Peng Wang; Qiuyue He; Yong Wang; Weidong Xiao; Hua Yang
Journal:  Oxid Med Cell Longev       Date:  2021-10-18       Impact factor: 6.543

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.